Search NLS News

AnaCardio has announced the completion of a USD 19 million Series A extension financing round, co-led by Novo Holdings, Pureos Bioventures and Sound Bioventures. Current investors Flerie, Industrifonden, and Fredrik and Ann-Helene Ljungström, also participated to complete the round.

Novo Nordisk and Valo Health have entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 diabetes, and cardiovascular disease based on Valo’s human dataset and computation powered by artificial intelligence (AI).

Stryker has announced a definitive agreement to acquire all of the issued and outstanding shares of common stock of Inari Medical for USD 80 per share in cash, representing a total fully diluted equity value of approximately USD 4.9 billion.

PolyPeptide Group has announces the planned doubling of solid-phase peptide synthesis (SPPS) capacity at its manufacturing site in Malmö, Sweden.

Before Christmas Finnish Combinostics announced that it has entered an agreement with the Swedish company SyntheticMR where SyntheticMR will acquire all shares in Combinostics.

BerGenBio has announced the appointment of Olav Hellebø as CEO.

We would like to thank our readers, subscribers and collaboration partners for a fruitful 2024, and we wish you all a most wonderful holiday season!

Genomic Medicine Sweden (GMS) and the Danish National Genome Center (DNGC) have renewed their memorandum of understanding to promote the development of personalized medicine in Sweden and Denmark.

As this year’s Nobel Prize winners were walking into Stockholm City Hall for festivities recently, the temperature was climbing below zero in the December night outside.

Journalist and documentary filmmaker Luis Jachmann has visited North Sweden to document Umeå’s role as a life science hub.